论文部分内容阅读
目的:观察呋塞米治疗产前妊娠高血压性心衰患者疗效。方法:将110例产前妊娠高血压性心衰患者随机分为呋塞米治疗组(治疗组)和常规治疗组(对照组),观察两组患者西地兰用量、心衰缓解时间、硝酸甘油的平均速度、治疗前后血压平均下降范围及治疗组用药前后血清钾的变化。结果:治疗组呋塞米平均用量60 mg。西地兰平均用量治疗组0.6 mg,对照组1.4 mg;心衰缓解时间治疗组3.8 h,对照组6.6 h,两组比较差异有统计学意义(P<0.01)。硝酸甘油的平均速度治疗组40μg/min,对照组60μg/min,两组比较差异有统计学意义(P<0.01)。治疗组治疗后收缩压平均下降42.12 mmHg,舒张压平均下降25.33 mmHg;对照组治疗后收缩压平均下降38.62 mmHg,舒张压平均下降23.51 mmHg,两组比较差异有统计学意义(P<0.01)。治疗组治疗前后血清钾平均值分别是3.66 mmol/L、3.37 mmol/L,治疗前后差异无统计学意义(P>0.05)。结论:产前妊娠高血压性心衰在强心、降压的基础上静注呋塞米能够较快的控制心衰,减少西地兰、硝酸甘油的用量,同时又可控制血压,血清钾下降不明显,是一种安全、可靠的治疗产前妊娠高血压性心衰理想药物之一。
Objective: To observe the curative effect of furosemide on patients with premature pregnancy-induced hypertension heart failure. Methods: One hundred and ten cases of prenatal pregnancy-induced hypertension were randomly divided into furosemide treatment group (treated group) and conventional treatment group (control group). The dosage of cedilanid, The average speed of glycerol, blood pressure before and after the average decline in the treatment group before and after treatment of serum potassium changes. Results: The average dosage of furosemide in the treatment group was 60 mg. The average dosage of cedilanid, 0.6 mg in the treatment group and 1.4 mg in the control group, and 3.8 h in the treatment group, and 3.8 h in the control group, the differences were statistically significant (P <0.01). Mean nitroglycerin treatment group 40μg / min, control group 60μg / min, the difference between the two groups was statistically significant (P <0.01). After treatment, the systolic blood pressure decreased by 42.12 mmHg and the diastolic blood pressure decreased by 25.33 mmHg in the treatment group. The average systolic blood pressure decreased by 38.62 mmHg and the diastolic blood pressure decreased by 23.51 mmHg in the control group. The difference was statistically significant (P <0.01). The average serum potassium in the treatment group before and after treatment was 3.66 mmol / L and 3.37 mmol / L, respectively, with no significant difference between before and after treatment (P> 0.05). Conclusions: Prenatal pregnancy-induced hypertensive heart failure (CHF) can be used to control heart failure quickly and reduce the dosage of cedilanid and nitroglycerin on the basis of cardioplegia and antihypertensive. At the same time, it can control blood pressure, serum potassium The decline is not obvious, is a safe and reliable one of the ideal drugs for the treatment of premature pregnancy-induced hypertension heart failure.